Literature DB >> 32755847

Impact of COVID -19 in cancer patients on severity of disease and fatal outcomes: A systematic review and meta-analysis.

Abhijeet Ashok Salunke1, Kunal Nandy2, Subodh Kumar Pathak3, Jaymin Shah4, Mayur Kamani2, Viswanth Kottakota2, Praveen Thivari3, Apurva Pandey5, Keval Patel2, Priyank Rathod2, Supreet Bhatt2, Pariseema Dave2, Shashank Pandya2.   

Abstract

BACKGROUND AND AIMS
BACKGROUND: Currently there is limited knowledge on cancer and COVID-19; we conducted a systematic review and meta-analysis to evaluate the impact of cancer on serious events including ICU admission rate and mortality in COVID 19.
METHODS: PubMed, Cochrane Central Register of Clinical Trials were searched on April 16, 2020, to extract published articles that reported the outcomes of cancer in COVID-19 patients. The search terms were "coronavirus" and "clinical characteristics" with no language or time restrictions. We identified 512 published results and 13 studies were included in the analysis.
RESULTS: There were 3775 patients, of whom 63 (1·66%) had a cancer. The pooled estimates of ICU admission in COVID 19 patients with and without cancer were 40% versus 8·42%.The odds ratio of ICU admission rates between the cancer and non-cancer groups was 2.88 with a 95% CI of 1·18 to 7·01 (p = 0·026). The pooled estimates of death rate in COVID -19 patients with and without cancer were 20·83% versus 7·82%. The odds ratio of death rates between the cancer and non-cancer groups was 2.25 with a 95% CI ranging from 0·71 to 7·10 with p value of 0·166. The pooled prevalence of cancer patients was 2% (95 CI 1-4).
CONCLUSIONS: Presence of cancer in COVID-19 leads to higher risk of developing serious events i.e. ICU admission, mechanical ventilation and mortality. The presence of cancer has a significant impact on mortality rate in COVID-19 patients.
Copyright © 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  COVID-19; Cancer; Corona disease; ICU Stay; Mortality rate; Non cancer; Oncology

Mesh:

Year:  2020        PMID: 32755847     DOI: 10.1016/j.dsx.2020.07.037

Source DB:  PubMed          Journal:  Diabetes Metab Syndr        ISSN: 1871-4021


  22 in total

1.  A systemic study on the vulnerability and fatality of prostate cancer patients towards COVID-19 through analysis of the TMPRSS2, CXCL10 and their co-expressed genes.

Authors:  Md Thosif Raza; Shagufta Mizan
Journal:  Genomics Inform       Date:  2022-09-30

2.  Effects of SARS-CoV-2 infections in patients with cancer on mortality, ICU admission and incidence: a systematic review with meta-analysis involving 709,908 participants and 31,732 cancer patients.

Authors:  Mehmet Emin Arayici; Nazlican Kipcak; Ufuktan Kayacik; Cansu Kelbat; Deniz Keskin; Muhammed Emin Kilicarslan; Ahmet Veli Kilinc; Sumeyye Kirgoz; Anil Kirilmaz; Melih Alihan Kizilkaya; Irem Gaye Kizmaz; Enes Berkin Kocak; Enver Kochan; Begum Kocpinar; Fatmanur Kordon; Batuhan Kurt; Hulya Ellidokuz
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-13       Impact factor: 4.322

3.  Response to Cottu, Bozec, Basse, and Paoletti.

Authors:  Hua Zhang; Han Han; Tianhui He; Kristen E Labbe; Adrian V Hernandez; Haiquan Chen; Vamsidhar Velcheti; Justin Stebbing; Kwok-Kin Wong
Journal:  J Natl Cancer Inst       Date:  2021-03-01       Impact factor: 13.506

4.  Effect of hydroxychloroquine on COVID-19 prevention in cancer patients undergoing treatment: study protocol for a randomized controlled trial.

Authors:  H Rahimi; A Allahyari; S Ataei Azimi; M Kamandi; Z Mozaheb; F Zemorshidi; M Khadem-Rezaiyan; A Bary; M Seddigh-Shamsi; M Moeini Nodeh
Journal:  Trials       Date:  2021-05-19       Impact factor: 2.279

5.  Impact of COVID-19 on cancer management in military hospitals of Saudi Arabia.

Authors:  Omar Al Zahrani; Ismail Ghorbel; Osama Mukhtar; Muneera Almajed; Hoda M Abdelazim; Muhammad N Hasan; Ahmad Mostafa; Aisha A Al Harbi; Ali Bajouda
Journal:  Saudi Med J       Date:  2021-12       Impact factor: 1.422

Review 6.  COVID-19 outcomes in paediatric cancer: A large scale pooled meta-analysis of 984 cancer patients.

Authors:  Amr Ehab El-Qushayri; Amira Yasmine Benmelouka; Abdullah Dahy; Mohammad Rashidul Hashan
Journal:  Rev Med Virol       Date:  2022-03-05       Impact factor: 11.043

7.  "Outcomes of COVID-19 infection in patients with hematological malignancies- A multicenter analysis from Pakistan".

Authors:  Adeeba Zaki; Salman Muhammad Soomar; Danish Hasan Khan; Hasan Shaharyar Sheikh; Raheel Iftikhar; Ayaz Mir; Zeba Aziz; Khadija Bano; Hafsa Naseer; Qamar Un-Nisa Chaudhry; Syed Waqas Imam Bokhari; Munira Shabbir-Moosajee
Journal:  PLoS One       Date:  2022-04-21       Impact factor: 3.752

8.  Pancytopenia and Profound Neutropenia as a Sequela of Severe SARS-CoV-2 Infection (COVID-19) With Concern for Bone Marrow Involvement.

Authors:  Jarelys M Hernandez; Ross Quarles; Seetha Lakshmi; Beata Casanas; Jennifer Eatrides; Erin McCoy; Charurut Somboonwit
Journal:  Open Forum Infect Dis       Date:  2021-01-18       Impact factor: 3.835

9.  COVID-19 Risk Factors for Cancer Patients: A First Report with Comparator Data from COVID-19 Negative Cancer Patients.

Authors:  Beth Russell; Charlotte L Moss; Kieran Palmer; Rushan Sylva; Andrea D'Souza; Harriet Wylie; Anna Haire; Fidelma Cahill; Renee Steel; Angela Hoyes; Isabelle Wilson; Alyson Macneil; Belul Shifa; Maria J Monroy-Iglesias; Sophie Papa; Sheeba Irshad; Paul Ross; James Spicer; Shahram Kordasti; Danielle Crawley; Kamarul Zaki; Ailsa Sita-Lumsden; Debra Josephs; Deborah Enting; Angela Swampillai; Elinor Sawyer; Paul Fields; David Wrench; Anne Rigg; Richard Sullivan; Mieke Van Hemelrijck; Saoirse Dolly
Journal:  Cancers (Basel)       Date:  2021-05-19       Impact factor: 6.639

10.  Impact of cancer on mortality and severity of corona virus disease 2019: A protocol for systematic review and meta-analysis.

Authors:  Yi Zhang; Hao Han; Yunling Tian; Jing Dong; Yage Yu; Yingying Kang; Lina Xing; Rongna Lian; Ruinian Zhang; Dairong Xie
Journal:  Medicine (Baltimore)       Date:  2020-10-30       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.